Nav: Home

Therapeutic substitution could help reduce money spent on prescription drugs

May 09, 2016

An extra $73 billion was spent between 2010 and 2012 on brand name medications and the practice of therapeutic substitution (substituting chemically different compounds within the same class of drugs for one another) could help to drive down those costs, according to a new study published online by JAMA Internal Medicine.

Therapeutic substitution is a controversial way to improve the efficiency of the pharmaceutical market because it is opposed by many physician organizations as an attack on physician autonomy.

Michael E. Johansen, M.D., M.S., of Ohio State University, Columbus, and Caroline Richardson, M.D., of the University of Michigan, Ann Arbor, used data on 107,132 individuals in the Medical Expenditure Panel Survey, along with their reported prescription medicine use, to estimate potential savings through therapeutic substitution. The authors looked at overall and out-of-pocket expenditures.

The study included drug classes that in a given year contained both a generic or widely accessible over-the-counter (OTC) drug and a brand name drug without an available chemically equivalent generic.

Of the 107,132 individuals, 62.1 percent reported using prescribed medicine between 2010 and 2012 and 31.5 percent used medication from an included drug. A branded drug from an included class was used by 16.6 percent of individuals compared with 24 percent who used a generic and 9.1 percent who used both, according to the results.

Overall, $760 billion was spent on prescription medications between 2010 and 2012. The extra money spent because of brand drug overuse accounted for 9.6 percent of total prescription medication expenditures. Total out-of-pocket expenditures between 2010 and 2012 were $175 billion, of which 14.1 percent were because of brand drug overuse, according to the results.

Drug classes where the most extra money was spent included statins, atypical antipsychotics, proton pump inhibitors, selective serotonin reuptake inhibitors and angiotensin receptor blockers, the study notes.

The authors note a number of study limitations, including estimates of pharmaceutical rebates and the overuse of branded drugs within drug classes.

"There was a large amount of excess expenditure on branded drugs between 2010 and 2012 in classes that could have incorporated therapeutic substitution. Although therapeutic substitution is controversial, it offers a potential mechanism to decrease drug costs if it can be implemented in a way that does not negatively affect quality of care," the authors conclude.
-end-
(JAMA Intern Med. Published online May 9, 2016. doi:10.1001/jamainternmed.2016.1704. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Media Advisory: To contact corresponding study author Michael E. Johansen, M.D., M.S., call Sherri Kirk at 614-293-3737 or email Sherri.Kirk@osumc.edu.

Video and audio content: A video and audio report is available for preview under embargo at this link. It will be available for download at this link on Friday at 2 p.m. ET with broadcast-quality video and audio files, B-roll, scripts, and other images. Please email JAMAReport@synapticdigital.com with any questions.

Other available related material:
  • Original Investigation: "Association of Industry Payments to Physicians with the Prescribing of Brand Name Statins in Massachusetts"
  • Editorial: "Promise and Peril for Generic Drugs"
  • Editor's Note: "Therapeutic Substitution - Should It Be Systematic or Automatic?"
  • Letters: "Prevalence and Predictors of Generic Drug Skepticism Among Physicians: Results of a National Survey"
  • Letters: "Generic Medication Prescription rates After Health System-Wide redesign of Default Options Within the Electronic Health Record"

To place an electronic embedded link in your story: Links will be live at the embargo time: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2016.1704

The JAMA Network Journals

Related Drugs Articles:

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.
Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.
Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.
Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.
People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.
Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.
Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.
Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.
New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.
New TB drugs possible with understanding of old antibiotic
Tuberculosis, and other life-threatening microbial diseases, could be more effectively tackled with future drugs, thanks to new research into an old antibiotic by the University of Warwick and the Francis Crick Institute.
More Drugs News and Drugs Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.